Clinical trial
Serotonergic Pharmacotherapy for Agitation of Dementia
NCT00009204 · Bruce Pollock, Other · Completed
Key facts
| NCT number | NCT00009204 |
|---|---|
| Title | Serotonergic Pharmacotherapy for Agitation of Dementia |
| Official title | Serotonergic Pharmacotherapy for Agitation of Dementia |
| Acronym | SPAD |
| Lead sponsor | Bruce Pollock, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dementia, Alzheimer Disease, Vascular |
| Intervention type | Drug |
| Interventions | Citalopram [Celexa], Perphenazine [Trilafon] |
| Start date | Sep 1, 1995 |
| Primary completion | Apr 1, 2000 |
| Completion | Apr 1, 2002 |
| First posted | Jan 24, 2001 |
| Last update posted | Jun 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: